Reverse Type 2 Diabetes: Predict Your Trajectory and Lower Your A1c
Type 2 diabetes can be put into remission for many people through a structured, doctor-led programme built around your own continuous glucose monitor. Remission means an A1c below 6.5% sustained for at least three months without glucose-lowering medication, as defined by the American Diabetes Association. It is not a cure, and results vary from person to person, but the science behind it is now well established. This page explains what reversal realistically means, the evidence it rests on, and how our programme helps you see and change your own metabolic trajectory before complications set in.
What "reversal" actually means
The word "reversal" is popular, but the clinically accurate term is remission. Type 2 diabetes develops when the body becomes resistant to insulin and the pancreas can no longer keep glucose in a normal range. A key driver is excess fat stored in the liver and pancreas, which interferes with how these organs handle glucose and insulin. Landmark research has shown that in people whose type 2 diabetes is caught early enough, that fat can be reduced and the underlying machinery can recover enough that blood glucose returns to a non-diabetic range without medication.
- DiRECT trial (Lancet, 2018; two-year data 2019): a primary-care weight-management programme achieved remission in a substantial share of participants, and remission was closely linked to how much weight people lost and kept off.
- Virta Health two-year data (2019): a physician-supervised low-carbohydrate approach with continuous remote monitoring reported durable reductions in A1c and in medication use.
- Diabetes Prevention Program (DPP/DPPOS): showed that structured lifestyle change sharply reduces progression from prediabetes to diabetes and continues to matter for many years.
- Look AHEAD: intensive lifestyle change improved weight, fitness and glycaemic control in people with established type 2 diabetes.
Two points matter above all. First, remission is most achievable earlier in the disease, generally within the first several years of diagnosis and before long-standing insulin dependence, because the pancreas still has reserve capacity. Second, remission can be lost if the changes that produced it are not maintained, which is why monitoring continues beyond the initial push. Type 1 diabetes, which is autoimmune, cannot be reversed by lifestyle, although the same tools still help with day-to-day control.
Your own CGM: seeing the invisible
A continuous glucose monitor (CGM) is a small sensor worn on the arm that reports your glucose every few minutes, day and night. For most people this is the first time they can actually watch how a specific meal, a walk, a poor night's sleep, or a stressful meeting moves their glucose. That feedback loop is the engine of behaviour change, because cause and effect become concrete instead of theoretical.
With your own CGM you can measure time in range (the share of the day your glucose stays within target), spot the specific foods that spike you personally, and confirm that a change is working long before your next lab A1c. Two people can eat the same rice dish and see completely different responses; only your own data can tell you which foods deserve a swap. Approximate retail options such as Libre, Dexcom, Stelo and Lingo have made sensors far more accessible without insurance. The challenge is no longer getting data but interpreting it, and our programme is built to help you turn the stream into a small number of high-impact decisions rather than an overwhelming graph.
An endocrinologist-led care team
Reversal is a medical process, not a wellness fad, so it belongs with clinicians. Our programme is led by an endocrinologist-supervised team and coordinated with coaches and dietitians who all work from the same data. That coordination matters most around medication: as your glucose improves, doses of insulin or sulfonylureas may need to come down to avoid dangerous lows, and getting the timing right requires clinical judgement. Never stop or change a medication on your own — dose changes are made with your clinician. GLP-1 medicines such as semaglutide (Ozempic, Wegovy) and dual agonists such as tirzepatide (Mounjaro) are prescription-only and clinician-supervised, and are used where they are clinically appropriate to support weight loss and control.
A coordinated team also means your nutrition, activity, sleep and medication are treated as one system rather than separate silos. When your coach suggests a food swap, your clinician sees the glucose response; when your labs shift, the plan adjusts. This is closer to how the successful trials were actually run than to a generic app plus an occasional appointment.
AI that predicts your reversal trajectory
We combine your CGM stream, labs, meals and activity into a metabolic model that projects where your A1c and time-in-range are heading if you keep your current pattern, and how that trajectory could change if you adjust one lever. It is a decision-support and screening aid, not a diagnostic device or a guarantee — confirm any clinical decision with your care team. The value is both motivational and practical: instead of waiting three months to find out whether a change worked, you see the projected effect in days and can double down on what helps.
- Baseline: labs, a structured assessment, and your first CGM week establish exactly where you are starting from.
- Personalised plan: meal timing, food swaps, movement and sleep targets tuned to your own data and your own cuisine.
- Trajectory review: the model projects your path and flags the single highest-impact change to make next.
- Iterate: your team reviews progress and adjusts the plan, including safe, clinician-led medication de-escalation as your numbers improve.
How progress is measured
Honest progress is measured, not asserted. We track a small set of markers that the evidence says actually matter, and we show them to you transparently rather than quoting a headline success rate that could not describe your individual situation.
| Marker | What it tells you |
|---|---|
| A1c | Average glucose over roughly three months; the anchor for the remission definition |
| Time in range | Day-to-day control from your CGM, which responds faster than A1c |
| Medication load | Whether doses can be safely reduced under clinician supervision |
| Weight and waist | Strongly linked to the likelihood of remission |
| Blood pressure and lipids | Because diabetes care is also cardiovascular care |
One annual payment, open to anyone
The programme is offered as one annual payment with no insurance required, so cost is predictable and you are not billed per visit or discouraged from reaching out to your team. Pricing is region-specific — see current pricing on the programme page. What you are really buying is the combination the evidence supports: structure, your own CGM, a supervising clinical team, culturally relevant food guidance, and tools that make your own data actionable. No single element does the work; it is the system working together that produces durable change.
Frequently Asked Questions
Is type 2 diabetes reversal permanent?
Remission can last for years, but it is maintained by keeping the changes that produced it. If old patterns return and weight comes back, glucose can rise again. Ongoing monitoring helps you catch drift early and act before your A1c climbs.
How fast can I see change?
CGM changes can appear within days, and A1c reflects roughly the previous three months, so meaningful A1c movement is usually visible by the second or third month. Results vary with your starting point and how consistently you engage.
Do I have to stop my medication?
No — and never on your own. As your numbers improve, your clinician may safely reduce doses. Some people reach remission off medication; others achieve much better control while still taking medicines. Both are good outcomes.
Can everyone reverse type 2 diabetes?
Not everyone. Remission is most likely earlier in the disease and with meaningful, sustained weight loss. Even when full remission is not reached, better control substantially lowers the risk of long-term complications in the eyes, kidneys, nerves and heart.